What Happened

City Therapeutics, an 81-person RNAi biotech based in Cambridge, MA, went public on Nasdaq with an upsized $200M IPO, trading under ticker CTY. The company offered 11.1 million shares at $18 each, above its initial expectation of 9.7 million shares, and gross proceeds could rise by an additional $30 million if underwriters exercise their option.

The funds are already earmarked: $30 million for CITY-FXI through a phase 1 study and into a mid-stage trial for knee surgery thrombosis; $20 million for a phase 1 study of CITY-RBP4 for Stargardt disease and geographic atrophy; and $40 million for CITY-TFR2, a GalNAc-conjugated siRNA targeting anemia, with a trial planned in China and potential expansion into chronic kidney disease and inflammatory conditions.

Who Is Affected

City Therapeutics itself is the primary beneficiary, but its existing partners—Biogen and Bausch + Lomb—stand to gain as the company scales. The IPO also signals opportunity for vendors serving clinical-stage biotechs, including CROs, clinical trial management software providers, and data infrastructure companies, as City ramps up multiple phase 1 and phase 2 studies.

The broader RNAi space is affected too: City was founded by Alnylam Pharmaceuticals pioneers, and its IPO follows ADARx Pharmaceuticals’ $446.3M public listing, underscoring renewed investor appetite for RNA-targeted therapeutics.

Market Impact

• Increased trial activity: City’s $90M in earmarked funds for three programs will drive demand for CRO services, site management, and patient recruitment, particularly in thrombosis, ophthalmology, and anemia.
• Infrastructure needs: Scaling from 81 employees to support multiple phase 1 and phase 2 trials will require investment in clinical data systems, regulatory compliance software, and lab equipment.
• Partnership leverage: Existing deals with Biogen and Bausch + Lomb may expand as City advances its pipeline, creating additional procurement opportunities for suppliers.
• SPAC activity: Frazier Life Sciences’ concurrent SPAC listing (raising $75M) indicates continued interest in biotech public offerings, potentially increasing the pool of funded companies seeking vendor services.

What to Watch

City’s next milestones include initiating the CITY-TFR2 trial in China later this year and expanding into chronic kidney disease and inflammatory bowel disease indications. The company’s ability to execute on its phase 1 and phase 2 plans will determine whether it becomes a repeat buyer of clinical services.

Also monitor the underwriters’ option exercise: if fully taken, City would gain an additional $30M, further accelerating its spending. The performance of ADARx Pharmaceuticals’ stock (currently trading near its IPO price) and the success of Frazier’s SPAC will signal whether the IPO window for RNAi biotechs remains open.

Related coverage

• ADARx scores upsized $446M IPO; City Therapeutics maps out Nasdaq plans
• TRex Bio raises $117M IPO; Retension Pharmaceuticals lists with $45M IPO
• TRex Bio and Retension Pharmaceuticals file for IPO; ADARx eyes up to $446M listing
• ADARx plans IPO to fund siRNA therapies